The U.S. Centers for Medicare & Medicaid Services (CMS) released 2025 data revealing a historic surge in disputes processed through the federal Independent Dispute Resolution (IDR) mechanism, with annual claims exceeding 2.5 million, up sharply from 1.5 million in 2024. The total value of IDR rulings surpassed $15 billion, more than tripling the previous year's figure.

Against this backdrop, Claritev Corporation, a healthcare technology and data analytics firm, has demonstrated significant market leadership in dispute management through its end-to-end services under the No Surprises Act. CMS data indicates that Claritev handled the highest volume of federal IDR disputes among non-payer entities, managing approximately 270,000 arbitration cases, a scale second only to the largest U.S. health insurers.

The No Surprises Act, enacted by the U.S. Congress in December 2020, is designed to protect patients from unexpected high medical bills. Claritev also excelled in dispute resolution efficiency. In 2025, the company's clients achieved a 20% acceptance rate for their offers in IDR rulings, significantly surpassing the industry average of 12%. This rate improved to 24% in the fourth quarter, compared to the industry's 15% average.

Additionally, Claritev utilized the qualifying payment amount method to price over one million claims and resolved approximately 400,000 disputes through pre-arbitration negotiations, effectively reducing the number of cases entering formal arbitration. The No Surprises Act aims to shield insured patients from certain unexpected out-of-network bills and limit their cost-sharing responsibilities.

The established IDR process allows health insurers and healthcare providers to settle payment disputes while excluding patients. Initially projected to generate fewer than 20,000 disputes annually, the actual volume has exceeded original estimates by more than 100 times. A trend report from Claritev found that nearly 50% of federal IDR applications reviewed by the company in 2025 had potential federal eligibility issues.

Claritev CEO Travis Dalton stated that the company's scale, expertise, and technology are helping clients navigate an increasingly complex dispute process while upholding the law's fundamental commitment to patients.